Trial Profile
A PHASE 1, DOUBLE-MASKED, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, TOLERABILITY, IMMUNOGENICITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF MULTIPLE ESCALATING DOSAGES OF RN6G (PF-04382923) IN SUBJECTS WITH ADVANCED DRY, AGE-RELATED MACULAR DEGENERATION (AMD) INCLUDING GEOGRAPHIC ATROPHY
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 May 2022
Price :
$35
*
At a glance
- Drugs PF 4382923 (Primary)
- Indications Dry age-related macular degeneration
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Pfizer
- 05 May 2014 New trial record